Pathos AI Raises 237M in Series E Funding
Pathos AI secured $237 million in a Series E funding round and partnered with Bristol Myers Squibb and Tempus AI. The collaboration aims to leverage artificial intelligence for neurological drug development.
Xurve View
Insights:
Xurve View
Pathos AI secured $237M in a Series E funding round led by BRISTOL-MYERS SQUIBB CO, valuing the New York-based firm at $3B. The financing fuels artificial intelligence drug development in Alzheimer's disease and neurological disorders. The initiative pairs the startup with major pharmaceutical players to accelerate targeted clinical trials.
